Clinical Trial Update: Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating simplification to dolutegravir plus lamivudine and its impact on HIV-1 reservoirs has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Epivir (Lamivudine)
• Tivicay (dolutegravir)

Snippet

Sponsor: University of Liege | Conditions: HIV Infections | Phase 3 | Status: COMPLETED